A Cardiovascular Risk Assessment Model According to Behavioral, Psychosocial and Traditional Factors in Patients With ST-Segment Elevation Myocardial Infarction (CRAS-MI): Review of Literature and Methodology of a Multi-Center Cohort Study

Roohafza, Hamidreza; Noohi, Feridoun; Hosseini, Shervin Ghaffari; Alemzadeh‐Ansari, Mohammad Javad; Bagherieh, Sara; Marateb, Hamid Reza; Mansourian, Marjan; Mousavi, Aboozar Fakhr; Seyedhosseini, Mostafa; Farshidi, Hossein; Ahmadi, Nastaran; Yazdani, Aram; Sadeghi, Masoumeh

doi:10.1016/j.cpcardiol.2022.101158

Cited by 4 publications

(5 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 2005, the mortality rate for AMI patients has increased rapidly, with female patients showing a tendency to have a higher mortality rate than male patients ( Shengshou et al, 2019 ). AMI has a high morbidity and mortality rate, posing a serious threat to human health and life safety, and placing a heavy burden on patients and their families ( Roohafza et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Effect of adjuvant therapy with compound danshen drip pill on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction: a systematic review and meta-analysis

Fan,

Liu,

Song

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Objectives: The purpose of the study was to comprehensively evaluate efficacy and safety of CDDP in patients with AMI undergoing PCI.Methods: A computerised search was conducted on the CNKI, WF, VIP, CBM, PubMed, Embase, Web of Science, and Cochrane Library databases for RCTs of CDDP adjuvant therapy for AMI up to May 2023. STATA 17.0 was used to perform meta-analyses, sensitivity analyses, subgroup analyses, meta-regression, and publication bias assessments. TSA 0.9.5.10 Beta was used for trial sequential analysis (TSA). Evidence confidence of meta results was evaluated by GRADE (Grading of Recommendations Assessment, Development and Evaluation) according to the instructions.Results: The results of the meta-analysis showed that CDDP combined with conventional western treatment (CWT) was superior to CWT in increasing LVEF and TCER and decreasing LVEDD, hs-CRP, IL-6 and TNF-α. The quality of evidence for TCER was moderate, LVEF, LVEDD, IL-6, and TNF-α were low. The TSA results showed that the total number of samples collected in this study met the requirements for meta-analysis and excluded the possibility of false positives, further confirming the efficacy of CDDP for the treatment of AMI undergoing PCI.Conclusion: Adjuvant treatment of AMI with CDDP has shown exciting and safe benefits in improving cardiac function and reducing inflammatory response in patients with AMI undergoing PCI, but the quality of some of the included studies was poor, and the results should be interpreted with caution until further confirmation by well-designed RCTs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/#recordDetails], identifier [CRD42023453293].

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of adjuvant therapy with compound danshen drip pill on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction: a systematic review and meta-analysis

Fan,

Liu,

Song

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The WHO risk calculation tool may be utilized for individual risk assessment (ten‐year risk for a severe or lethal cardiovascular event); this is also available online or as an app 36,37 . The same applies to patients with a previous myocardial infarction, stroke, or venous thromboembolic event 38–40 . In individual, exceptional cases, concomitant medical treatment to prevent thrombosis may be tried in order to decrease the individual patient's risk 41 .…”

Section: Recommendationsmentioning

confidence: 99%

“…36,37 The same applies to patients with a previous myocardial infarction, stroke, or venous thromboembolic event. [38][39][40] In individual, exceptional cases, concomitant medical treatment to prevent thrombosis may be tried in order to decrease the individual patient's risk. 41 Established anticoagulation or pharmaceutical platelet aggregation inhibition should be taken into account.…”

Section: Recommendationsmentioning

confidence: 99%

Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases

Wohlrab

Kegel

Große

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryIn accordance with article 20 of Regulation (EC) No 726/2004, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has re‐evaluated the safety of Janus kinase inhibitors for the treatment of inflammatory diseases and formulated safety information deviating from the previous indications in the respective summary of product characteristics of the products concerned. These refer to the consideration of a possibly increased risk of venous thromboembolic or severe cardiovascular events, an increased infection rate and an increase in the prevalence of skin cancer across drugs and indications. Therefore, in patients with independent risk factors (age 65 years and older, smokers or former smokers, patients with oral contraception or hormone replacement therapy and other risk factors), it is recommended to use Janus kinase inhibitors therapeutically only if there are no suitable treatment alternatives. To facilitate a pragmatic and thorough detection of high‐risk patients in everyday clinical practice, an interdisciplinary checklist was developed that is suitable as a working tool from the perspective of the dermatologist.

show abstract

“…36,37 Gleiches gilt für Patienten, die in der Anamnese bereits einen Herzinfarkt, einen Schlaganfall oder ein venöses thromboembolisches Ereignis aufweisen. [38][39][40] Im Ausnahmefall kann dann eine therapiebegleitende medikamentöse Thromboseprophylaxe zur individuellen Risikominimierung im Einzelheilversuch erwogen werden. 41 Eine bereits vorbestehende Antikoagulation oder medikamentöse Thrombozytenaggregationshemmung sollten dabei berücksichtigt werden.…”

Section: Handlungsempfehlungenunclassified

“…Zur individuellen Risikoabschätzung (10‐Jahres‐Risiko für ein schwerwiegendes oder letales kardiovaskuläres Ereignis) kann das Risikoberechnungsverfahren der WHO, welches auch online und als App verfügbar ist, genutzt werden 36,37 . Gleiches gilt für Patienten, die in der Anamnese bereits einen Herzinfarkt, einen Schlaganfall oder ein venöses thromboembolisches Ereignis aufweisen 38–40 . Im Ausnahmefall kann dann eine therapiebegleitende medikamentöse Thromboseprophylaxe zur individuellen Risikominimierung im Einzelheilversuch erwogen werden 41 .…”

Section: Handlungsempfehlungenunclassified

Handlungsempfehlungen zur Risikominimierung beim Einsatz von Januskinase‐Inhibitoren zur Therapie chronisch‐entzündlicher Hauterkrankungen

Wohlrab

Kegel

Große

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDer Ausschuss für Risikobewertung (PRAC) der Europäischen Arzneimittelagentur (EMA) hat gemäß Artikel 20 der Verordnung (EG) Nr. 726/2004 die Sicherheit für Januskinase‐Inhibitoren für die Behandlung von Entzündungserkrankungen neu bewertet und von den bisherigen Hinweisen in den jeweiligen Fachinformationen der betreffenden Präparate abweichende Sicherheitsangaben formuliert. Diese beziehen sich arzneistoff‐ und indikationsübergreifend auf die Beachtung eines möglicherweise erhöhten Risikos für venöse thromboembolische oder schwere kardiovaskuläre Ereignisse, eine erhöhte Infektionsrate sowie eine Erhöhung der Prävalenz von Hautkrebs. Deshalb wird empfohlen, bei Patienten mit unabhängigen Risikofaktoren (Alter ab 65 Jahre, Raucher oder ehemalige Raucher, Patientinnen mit oraler Kontrazeption beziehungsweise Hormonersatztherapie sowie anderen Risikofaktoren) Januskinase‐Inhibitoren nur dann therapeutisch einzusetzen, wenn es keine geeigneten Behandlungsalternativen gibt. Um im klinischen Alltag eine pragmatische und sorgfältige Erfassung von Risikopatienten zu ermöglichen, wurde interdisziplinär eine Checkliste erarbeitet, die aus der Perspektive des Dermatologen als Arbeitsmittel geeignet ist.

show abstract

A Cardiovascular Risk Assessment Model According to Behavioral, Psychosocial and Traditional Factors in Patients With ST-Segment Elevation Myocardial Infarction (CRAS-MI): Review of Literature and Methodology of a Multi-Center Cohort Study

Cited by 4 publications

References 77 publications

Effect of adjuvant therapy with compound danshen drip pill on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction: a systematic review and meta-analysis

Effect of adjuvant therapy with compound danshen drip pill on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction: a systematic review and meta-analysis

Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases

Handlungsempfehlungen zur Risikominimierung beim Einsatz von Januskinase‐Inhibitoren zur Therapie chronisch‐entzündlicher Hauterkrankungen

Contact Info

Product

Resources

About